The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can significantly improve symptoms.

EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients unresponsive to other treatments.

Eli Lilly said on Tuesday Japan's health ministry has approved donanemab, its drug for Alzheimer's disease, providing patients with another treatment option after Eisai and Biogen's Leqembi received the nod in September last year.

Japan, with its rapidly aging population, is expected to have more than 5 million patients with dementia by 2030. Alzheimer’s is the most common form of dementia, accounting for more than 67% of cases,